Walvax Biotechnology Co., Ltd. (SHE: 300142)
China
· Delayed Price · Currency is CNY 15.96
+0.07 (0.44%)
Nov 15, 2024, 10:22 AM CST
Walvax Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 122.37 | 419.39 | 728.65 | 427.75 | 1,003 | 141.97 | Upgrade
|
| Depreciation & Amortization | 317.23 | 317.23 | 264.93 | 143.84 | 123.95 | 76.63 | Upgrade
|
| Other Amortization | 16.1 | 16.1 | 10.57 | 5.71 | 4.46 | 5.59 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.83 | 0.83 | 0.38 | -0.23 | 1.08 | 0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 11.31 | 11.31 | 1.66 | 5.11 | 2.41 | 3.96 | Upgrade
|
| Loss (Gain) From Sale of Investments | 227.64 | 227.64 | 187.54 | 222.86 | -285.29 | -19.31 | Upgrade
|
| Provision & Write-off of Bad Debts | 39.72 | 39.72 | -1.28 | -4.95 | -7.29 | -15.39 | Upgrade
|
| Other Operating Activities | 290.94 | 295.46 | 324.44 | 154.22 | 180.33 | 5.8 | Upgrade
|
| Change in Accounts Receivable | 535.7 | 535.7 | -1,241 | -614.65 | -1,495 | -72.91 | Upgrade
|
| Change in Inventory | -134.9 | -134.9 | -178.79 | -390.03 | -170.51 | -76.77 | Upgrade
|
| Change in Accounts Payable | -593.87 | -593.87 | 1,075 | 762.2 | 755.66 | 100.77 | Upgrade
|
| Operating Cash Flow | 832.24 | 1,134 | 1,201 | 705.28 | 114.19 | 62.02 | Upgrade
|
| Operating Cash Flow Growth | -30.13% | -5.64% | 70.36% | 517.62% | 84.13% | - | Upgrade
|
| Capital Expenditures | -669.41 | -945.52 | -1,091 | -1,103 | -407.13 | -351.82 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.39 | 0.74 | 0.34 | 3.73 | 4.47 | 0.2 | Upgrade
|
| Divestitures | 140 | 140 | 149.39 | 75.68 | 75 | 567.48 | Upgrade
|
| Investment in Securities | -182 | -10 | - | 41.18 | -407.56 | -26 | Upgrade
|
| Other Investing Activities | -695.18 | 6.78 | 6.26 | 5.74 | 5.22 | 3.14 | Upgrade
|
| Investing Cash Flow | -1,406 | -807.99 | -935.19 | -977.15 | -730 | 193 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 40 | - | Upgrade
|
| Long-Term Debt Issued | - | 499.31 | 393.82 | 410 | - | - | Upgrade
|
| Total Debt Issued | 305.06 | 499.31 | 393.82 | 410 | 40 | - | Upgrade
|
| Short-Term Debt Repaid | - | -189.19 | - | - | - | -30 | Upgrade
|
| Long-Term Debt Repaid | - | -78.61 | -405.35 | -149.73 | - | - | Upgrade
|
| Total Debt Repaid | -342.36 | -267.8 | -405.35 | -149.73 | - | -30 | Upgrade
|
| Net Debt Issued (Repaid) | -37.3 | 231.51 | -11.54 | 260.27 | 40 | -30 | Upgrade
|
| Issuance of Common Stock | - | 18.9 | 397.11 | 1,221 | 150.21 | - | Upgrade
|
| Repurchase of Common Stock | -72.21 | -72.21 | -286.42 | - | - | - | Upgrade
|
| Common Dividends Paid | -29.02 | -19.98 | -50.11 | -83.31 | -31.73 | -68.68 | Upgrade
|
| Other Financing Activities | 263.46 | 78.43 | 45.77 | 338.48 | 56.6 | -261.95 | Upgrade
|
| Financing Cash Flow | 124.93 | 236.64 | 94.82 | 1,736 | 215.08 | -360.64 | Upgrade
|
| Foreign Exchange Rate Adjustments | -5.79 | 2.27 | 4.07 | -0.12 | -1 | -0.21 | Upgrade
|
| Net Cash Flow | -454.81 | 564.69 | 365.19 | 1,464 | -401.73 | -105.83 | Upgrade
|
| Free Cash Flow | 162.83 | 188.25 | 110.31 | -398.21 | -292.94 | -289.81 | Upgrade
|
| Free Cash Flow Growth | -24.08% | 70.65% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 5.26% | 4.58% | 2.17% | -11.50% | -9.97% | -25.85% | Upgrade
|
| Free Cash Flow Per Share | 0.10 | 0.12 | 0.07 | -0.25 | -0.19 | -0.19 | Upgrade
|
| Cash Income Tax Paid | 157.24 | 264.12 | 309.57 | 244.55 | 212.66 | 242.9 | Upgrade
|
| Levered Free Cash Flow | 19.2 | 14.42 | -495.85 | -257.05 | -1,023 | 135.8 | Upgrade
|
| Unlevered Free Cash Flow | 25.37 | 18.14 | -491.4 | -253.44 | -1,022 | 154.9 | Upgrade
|
| Change in Net Working Capital | -143.71 | -171.07 | 370.62 | -120.6 | 1,463 | -249.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.